Concepedia

Nicholas Vitale

NV

Statistics

Publications

7

Citations

480

H-Index

7

Active since

1997

Affiliations

Arvinas (United States)(Current)

Yale University

University of New Haven

Nicholas Vitale is an author at Arvinas (United States) specializing in androgen receptor targeting, prostate cancer, and molecular oncology.

ORCID

Publications per year

1997–2024

7

Publications

7

ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.

Taavi K. Neklesa, Lawrence B. Snyder, Ryan R. Willard et al. · Journal of Clinical Oncology · 2019 · 207 citations

, , +16

Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer

Lawrence B. Snyder, Taavi K. Neklesa, Xin Chen et al. · Cancer Research · 2021 · 72 citations

, , +16

Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader

Lawrence B. Snyder, Taavi K. Neklesa, Ryan R. Willard et al. · Molecular Cancer Therapeutics · 2024 · 69 citations · Full text

, , +16

Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer

Taavi K. Neklesa, Lawrence B. Snyder, Ryan R. Willard et al. · Cancer Research · 2018 · 62 citations

, , +17

In-vitro development of refrozen mouse embryos

Nicholas Vitale, M. W. Myers, R.S. Denniston et al. · Human Reproduction · 1997 · 28 citations · Full text

, , +17

1–5 of 7